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Peroxisome proliferator-activated receptorδ (PPARδ) regulates a multiplicity of physiological processes associated with glucose
and lipid metabolism, inﬂammation, and proliferation. One or more of these processes likely create risk factors associated with the
ability of PPARδ agonists to promote tumorigenesis in some organs. In the present study, we describe a new gastric tumor mouse
model that is dependent on the potent and highly selective PPARδ agonist GW501516 following carcinogen administration. The
progression of gastric tumorigenesis was rapid as determined by magnetic resonance imaging and resulted in highly metastatic
squamous cell carcinomas of the forestomach within two months. Tumorigenesis was associated with gene expression signatures
indicative of cell adhesion, invasion, inﬂammation, and metabolism. Increased PPARδ expression in tumors correlated with
increased PDK1, Akt, β-catenin, and S100A9 expression. The rapid development of metastatic gastric tumors in this model will be
useful for evaluating preventive and therapeutic interventions in this disease.
1.Introduction
Gastric cancer is the second leading cause of cancer-related
deathglobally,particularlyindevelopingcountries,duetoits
metastatic nature at the time of diagnosis [1, 2]. Among the
many risk factors for gastric cancer are diet, smoking, and
inﬂammation associated with H. pylori infection [3–5] that
are likely exacerbated in patients with proinﬂammatory gene
polymorphisms [6].
PPARs are ligand-dependent nuclear receptors that
regulate expression of a multiplicity of genes associated
with metabolic disorders, such as type II diabetes and
lipodystrophies [7, 8]. PPARs consist of the α, γ and δ
isotypes that regulate not only glucose and lipid metabolism,
but also proliferation, inﬂammation, and angiogenesis [9–
13]. PPARδ expression is increased in breast, colon, and
head and neck cancers [9, 14–17] and is associated with a
more aggressive phenotype in breast cancer cells [18]. The
selectivePPARδ agonistGW501516actsasatumorpromoter
in mammary carcinogenesis [19] and colon tumorigenesis
[15, 20, 21], whereas disruption of PPARδ expression blocks
mammary [22] and colon tumorigenesis [23, 24]. PPARδ is
regulated by risk factors implicated in cancer progression,
including K-Ras [25], Wnt [26], and Pges/Cox2 [22, 27],
and is associated with activation of angiogenesis [20, 28–30].
PPARδ regulates proinﬂammatory signaling through NFκB
andIL-1β[31],andisactivatedbymetabolitesofarachidonic
acid metabolism that serve as PPAR ligands [14, 29, 32].
Notwithstanding these results, there are several reports
showing that azoxymethane-induced colon carcinogenesis is
increased in PPARδ nullizygous mice [33, 34] and by the
selective PPARδ ligand GW0742 [35]( r e v i e w e di n[ 36]).2 PPAR Research
Diﬀerencesbetweenthevariousnullizygousmodelsthatmay
account for some of these disparities have been discussed
[9, 21].
HerewedemonstratethatactivationofPPARδ byaselec-
tive agonist, GW501516, rapidly induces highly metastatic
gastric tumors following carcinogen administration, which
expressed a markedly increased inﬂammatory gene expres-
sion signature. These ﬁndings suggest a crucial role for
PPARδ in the progression of this disease.
2.MaterialsandMethods
2.1. Materials. GW501516 was synthesized as previously
described [37] and was provided by the Chemoprevention
Branch, National Cancer Institute, NIH, Bethesda, MD.
2.2. Carcinogenesis. DMBA (Sigma-Aldrich, St Louis, MO)
was dissolved in cottonseed oil at a concentration of
10mg/ml, and six week-old female FVB mice were admin-
istered 4 weekly doses of 1mg DMBA by gavage. Animals
were fed a standard diet or a diet supplemented with 0.005%
(w/w) GW501516 beginning one day after the last dose of
DMBA as previously described [19]. Mice were euthanized
when gastric tumors reached ≥2cm3 as determined by MRI
imaging or if mice became moribund. All protocols were
approved by the Georgetown University Animal Care and
Use Committee.
2.3. Magnetic Resonance Imaging. MRI was performed on
a 7.0 Tesla Bruker horizontal spectrometer/imager with
a 20cm bore equipped with 100gauss/cm microimaging
gradients and run by Paravision 4.0 software in the Preclini-
cal Imaging Research Laboratory, Lombardi Comprehensive
Cancer Center. Mice were anesthetized using 1.5% isoﬂurane
and 30% nitrous oxide, positioned in a custom-made
stereotaxic animal holder with temperature and respiration
control, and imaged in a 72mm birdcage radiofrequency
volume coil as previously described [38]. The imaging
protocol used was a T2-weighted RARE (rapid acquisition
with refocused echos) two-dimensional sequence with the
following parameters: Matrix: 256, TR: 5822msec, TE:
36msec, number of averages: 4, RARE factor: 8, FOV:
4.0cm, number of slices: 4, slice thickness: 0.5mm, and with
respiratory gating to account for breathing movement.
2.4.HistopathologyandImmunohistochemistry(IHC). Stom-
ach and tumors were excised, and formalin-ﬁxed, paraﬃn-
embedded sections were prepared for H&E staining and
IHC. Antigen retrieval was carried out by incubation of
tissue sections in 10mM sodium citrate buﬀer (pH 6.0) for
2 0 m i na tas u b b o i l i n gt e m p e r a t u r ei na ne l e c t r i cs t e a m e r
as previously described [19, 39]. Endogenous peroxidase
activitywasquenchedwith3%hydrogenperoxidefor10min
and incubated for 30min with blocking solution (10%
goat serum in Tris-buﬀered saline), followed by incubation
overnight at 4◦C with the appropriate primary antibody
diluted in blocking solution. Biotin-conjugated secondary
antibodies were diluted in TBS containing 0.1% Tween-20
and incubated for 30min at room temperature using the
ABC Vectastain (Vector Laboratories) detection system and
diaminobenzidine (Pierce), and slides were counterstained
with Harris-modiﬁed hematoxylin (Fisher Scientiﬁc) and
dehydrated and mounted in Permount (Fisher Scientiﬁc).
The following antibodies and their dilutions were used: anti-
CK14 (1:200, ms-115-P1, Neomarkers), anti-CK18 (1:200,
sc-7197, Santa Cruz Biotechnology), PDK1 (1:50, sc-17765,
Santa Cruz Biotechnology), anti-pS473 Akt (1:200, 40515,
Cell Signaling Biotechnology), anti-β-catenin (1:50, sc-
7963, Santa-Cruz Biotechnology) and anti-S100a9 (1:50, sc-
65580, Santa Cruz Biotechnology).
2.5. Gene Microarray Analysis. Three groups of tissues were
analyzed: (1) gastric tumors, (2) forestomach (nonglan-
dular) from GW501516-treated mice, and (3) forestomach
from DMBA-treated mice. Tissue was excised, washed in
phosphate-buﬀeredsaline,andstoredinRNAlater(Ambion)
at −20
◦C until RNA extraction. Tissue was snap-frozen in
liquid nitrogen, pulverized in a mortar and pestle, and RNA
extracted using an RNeasy Mini Kit (Qiagen) according to
the manufacturer’s protocol. RNA purity was assessed by
an A260/A280 ratio of ≥1.9, and by the integrity of 18S
and 28S rRNA using an Agilent microﬂuidic chip. Array
analysis was carried out on cRNA prepared from equal
amounts of RNA (1μg) pooled from 5 mice per group
as previously described [19, 40]. Biotin-labeled cRNA was
fragmented at 94◦C for 35min and hybridized overnight
to an Aﬀymetrix mouse 430A 2.0 GeneChip representing
approximately 14,000 annotated mouse genes. GeneChips
were scanned with an Agilent Gene Array scanner, and grid
alignment and raw data generation with the Aﬀymetrix
GeneChip Operating software 1.1. A noise value (Q)b a s e d
on the variance of low-intensity probe cells was used to
calculate a minimum threshold for each GeneChip. Samples
were averaged and data reﬁned by eliminating genes with
signal intensities <300 in both comparison groups, and
heat maps were generated from ≥3-fold changes in gene
expressionnormalizedtountreatedforestomachusingunsu-
pervised hierarchical cluster analysis as previously described
[41].GeneontologyanalysisutilizedAriadnePathwayStudio
version 7.1
2.6.QuantitativeReal-TimePolymeraseChainReaction(qRT-
PCR). Total RNA was extracted as described above, and
equal amounts of RNA (1μg) were pooled from each group
(ﬁve samples per group) and reverse transcribed with the
Omniscript RT kit (Qiagen) in a total volume of 20μL
as previously described [19, 39]. PCR was performed in
triplicate using an ABI-Prism 7700 (Applied Biosystems,
Foster City, CA) with SYBRGreen I detection (Qiagen)
according to the manufacturer’s protocol. Ampliﬁcation
usingtheappropriateprimers(seeTableS1insupplementary
material available at doi:10.1155/2010/571783) was con-
ﬁrmed by ethidium bromide staining of the PCR products
on an agarose gel. The expression of each target gene was
normalized to GAPDH and is presented as the ratio ofPPAR Research 3
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Figure 1: PPARδ agonist GW501516 induces gastric tumorigenesis after DMBA treatment. (a) In vivo axial T2-weighted abdominal MR
Images showing gastric tumor progression at the indicated time points; d, number of days animals were administered the GW501516-
supplemented diet. Tumor growth initiated in the forestomach (arrow) at 19 days, rapid tumor growth between 27 and 50 days, and tumor
invasion through the stomach (arrow) at 56 days. (b) Gross morphology of tumors at indicated time points. Forestomach (∗), gastric tumors
(T)andmetastases(arrows)areindicated.Tumorisconﬁnedwithinthestomachat20days.Invasionofprimarytumorthroughthestomach
(T) and metastases (arrow) were evident at 56 days, and intraperitoneal metastases along the abdominal wall (white arrows) occurred at 70
days.4 PPAR Research
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Figure 2: Pathophysiology of gastric tumorigenesis. (A) Histological changes in the forestomach after GW501516 and/or DMBA treatment.
Upper panel: StereoscopicimagesofH&Estainedsectionsofthestomachin(a)untreated,(b)DMBA-treated,(c,d)DMBAplusGW501516-
treated mice, and (e) metastases of the abdominal wall. Lower panel: higher magniﬁcation (200x) of the boxes in areas in the upper panel.
Insets,magniﬁcation 400x. (a) Morphology of the normal forestomach wall. (b) Squamous epithelial hyperplasia, where the basal membrane
is well deﬁned. (c) Squamous cell carcinoma. (d) Invasive squamous cell carcinoma showing disruption of the basement membrane. (e)
Metastatic squamous carcinoma showing invasion into the abdominal wall. (B) Histological changes in the stomach and esophagus after
treatment with either GW501516 or DMBA. H&E sections of the forestomach wall (a, b, c) and esophagus (d, e, f) six months after
administration of GW501516 or ﬁve months after treatment with DMBA. Both GW501516 and DMBA were associated with increased
keratinization (∗) of squamous epithelium (arrow). Magniﬁcation 400x. (C) Cytokeratin 14 (CK14) and cytokeratin18 (CK18) expression
in gastric tissue and tumors. Squamous epithelium of the forestomach (a), gastric mucosa (b), and gastric tumors (c, d). Tumors are
CK14+/CK18
− indicating a squamous epithelial origin. Magniﬁcation 200x, insets, 400x.PPAR Research 5
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Figure 3: Diﬀerential gene expression in GW501516-treated stomach and gastric tumors. Gene microarray analysis was carried out
with pooled RNA samples prepared from either ﬁve tissue samples of forestomach from untreated and GW501516 treated mice or six
gastric tumors. Heat maps represent unsupervised hierarchical clustering of ≥3-fold changes in signal intensity normalized to untreated
forestomach. (a) Heatmap of GW501516-treated versus stomach representing 42 genes. (b) Tumor versus stomach representing 811 genes.
(c) qRT-PCR analysis of the relative changes in gene expression in the stomach after GW501516 treatment (GW501516), and in tumors
(Tumor). GW501516 treated: array, cross-hatch;q R T - P C R ,diagonal; Tumors: array, black;q R T - P C R ,white.6 PPAR Research
Table 1: Gastric tumor occurrence after treatment with DMBA and
GW501516.
Treatment group No. animals No. animals with tumors
DMBA 10 0
GW501516 10 0
DMBA+GW501516 15 12
the target gene to GADPH expression calculated using the
formula, 2−ΔCt,w h e r eΔCt = CtTarget −Ct18s.
3. Results
3.1. PPARδ Agonist GW501516 Rapidly Promotes Gastric
Tumorigenesis. Mice maintained on a diet supplemented
with PPARδ agonist GW501516 following carcinogen
administration resulted in the rapid development of gastric
tumors in 12/15 animals, whereas treatment with either
GW501516 or DMBA alone was not tumorigenic (Table 1).
To follow the onset and progression of tumorigenesis more
precisely, ﬁve mice were monitored by MRI (Figure 1(a)).
Tumors were visible as early as 19 days after beginning the
GW501516 diet and appeared to initiate in the forestomach
(Figure 1(a)). By 50 days, tumor had ﬁlled the stomach
lumen, and by 56 days it had extravasated through the
gastric wall (Figure 1(a)). Gross inspection of the stomach
conﬁrmed that the tumor was conﬁned within the stomach
at day 20 but had invaded through the stomach wall forming
local metastases by day 56 (Figure 1(b)). Mice showed
signs of morbidity between days 63 and 70 (mean survival
67 days), where metastases were present throughout the
mesentery and adjacent serosal organ surfaces including the
abdominal wall (Figure 1(b)).
Primary tumors and metastases were uniformly squa-
mous cell carcinomas with varying degrees of keratinization
(Figure 2(A)). Animals fed the GW501516 diet for six
months without prior DMBA treatment did not exhibit
hyperplasia or dysplasia (Figure 2(B)), and DMBA treat-
ment alone produced squamous cell hyperplasia of the
forestomach without signs of dysplasia (Figures 2(A) and
2(B)). No changes occurred in the gastric mucosa resulting
from DMBA and GW501516 treatment alone (data not
shown), and esophageal squamous epithelium was unaf-
fected by DMBA treatment (Figure 2(B)). Gastric tumors
were positive for the squamous basal cell marker CK14, and
negative for the columnar epithelial cell marker CK18 [42]
(Figure 2(C)).
3.2. Diﬀerential Gene Expression in Gastric Tumors and Stom-
ach. Tumors manifested a marked inﬂammatory phenotype
denoted by increased expression of chemokines Cxcl-1,-2,
-5,-9,-14 and Ccl-2,-3,-8, S100a8, S100a9, and S100a3 and
interleukins IL-1β, IL-6, and IL-24 (Table 2, Figure 3(b),a n d
Table S2). In addition to these changes, increased expression
of prostaglandin metabolism genes Ptgs2/Cox2 and Ptges
and reduced expression of PPARγ and PPARα were noted.
To determine if these changes were tumor speciﬁc, gene
expression was assessed in stomach tissue after treatment
with either GW501516 for seven days (Figure 3(a), Table S3)
or DMBA for four weeks (Table S4). GW501516 increased
expression of only ﬁve genes ≥3-fold, Angptl4, Cyp2b10,
Cfd/Adipsin, Adipoq and Chi3l4 and markedly reduced
expression of Gast, Ccla3, Glycam1, Spp1, Serpina1a, Cela1,
Cldn2, and Fabp2 (Table S3). DMBA increased expression of
S100a8, S100a9, and Ccl8 4–10-fold and reduced expression
of the same subset of genes as GW501516 (Table S4). Thus,
changes in Gast, Ccla3, Glycam1, Spp1, Serpina1a, Cela1,
Cldn2, and Fabp2 are a result of GW501516 treatment and
are not tumor speciﬁc. On the other hand, DMBA produced
aninﬂammatoryresponsedenotedbyincreaseS100A8,Ccl8,
and S100A9 although it was an order of magnitude less than
in tumors. The increase in Krt6a by DMBA is consistent
with increased keratinization in the stomach (Figure 2(B))
butwaslesspronouncedthanintumors.Real-timeqRT-PCR
analysis generally conﬁrmed the changes in expression of
several genes, including Cldn8, Cxcl1, Cxcl5, Foxg1, S100a8,
Angptl4, Cyp2b10, Vegfα and Spp1, Gast, Dkk1, Bmp3,
Bmp4, PPARα,a n dP P A R γ (Figure 3(c)).
TheexpressionofPPARδ and factors known to be associ-
ated with its signaling were assessed in tumors and forestom-
ach after GW501516 treatment (Figure 4). GW501516
increased nuclear localization of PPARδ in gastric squamous
epithelium and tumors, in contrast to its diﬀuse cytoplasmic
staining in untreated gastric tissue. GW501516 also elicited
strong pS473Akt and pT308Akt staining in basal cells and
in the submucosal layer, as well as in tumor and stromal
tissue, which correlated with more intense PDK1 expression.
β-Catenin was expressed in the nuclei of basal squamous
epithelial cells and was not altered by GW501516 treatment,
whereas tumors expressed increased β-catenin at cellular
junctions. S100a9 was absent in untreated gastric epithelium
but was expressed in endothelial and epithelial cells from
GW501516-treated mice. Tumors expressed S100a9 in a
diﬀuse pattern, with strong expression in blood vessels and
adjacent epithelial cells.
4. Discussion
The present study describes a new model of metastatic
gastric cancer that is dependent on the tumor promoting
activity of PPARδ agonist GW510516 following carcinogen
administration. In contrast to a previous study reporting
a low percentage of squamous cell carcinomas of the
forestomach by DMBA [43], our DMBA regimen produced
only forestomach hyperplasia without signs of dysplasia up
to ﬁve months after treatment (Figure 2(B)). This suggests a
high sensitivity of mouse forestomach squamous epithelium
to dysplasia, and the predilection of GW501516 to promote
tumors of this histotype [19]. This model diﬀers from
N-methyl-N-nitrosourea-induced gastric tumors in wild-
type and APCMin transgenic mice [44, 45]i nt h a ti ti s
dependent on both DMBA-induced mutagenesis and the
tumor-promoting eﬀects of GW501516. A feature of this
model is its short latency of approximately three weeks
in comparison to 10 to 20 weeks for NMU-treated wild-
type and APCMin mice. An important histopathological
distinction, and perhaps disadvantage of the GW501516PPAR Research 7
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Figure 4:ImmunohistochemicalanalysisofforestomachafterGW501516treatmentandgastrictumors.IHCdetectionofPPARδ,pS473Akt,
pT308 Akt, PDK1, β-catenin, and S100a9. Magniﬁcation: untreated and GW501516 treated, 400x; tumor, PPARδ,P D K 1 ,a n dβ-catenin,
200x;pT308Akt,pS473Akt,S100a9,and400x.Inset,2xoriginalmagniﬁcation.PPARδ showsdiﬀusereactivityinuntreatedgastricsquamous
epithelium, increased nuclear localization after GW501516 treatment, and strong nuclear expression in tumor and stromal cells (inset).
pS473Akt and pT308Akt expressed weak diﬀuse reactivity in untreated gastric tissue, increased staining in basal cells and the submucosal
cell layer after GW501516 treatment, and strong reactivity in tumor and stromal cells. PDK1 exhibited diﬀuse cytoplasmic localization
throughout the untreated squamous epithelium and was unchanged after GW501516 treatment, whereas PDK1 was increased in tumors
similarly to pS473Akt and pT308Akt. Nuclear β-catenin was present in basal cells of untreated squamous epithelium and was unchanged
afterGW501516treatment,whereastumorsexpressedincreasedβ-cateninatcellularjunctions(inset).S100a9wasundetectableinuntreated
tissue and was increased in blood vessels and squamous epithelium (inset), whereas tumors exhibited increased diﬀuse cytoplasmic staining.8 PPAR Research
Table 2: Diﬀerentially expressed genes in gastric tumors.
Gene Symbol Gene Name Fold Change
S100a8 S100 calcium-binding protein A8 (calgranulin A) 229.0
S100a9 S100 calcium-binding protein A9 (calgranulin B) 74.6
S100a3 chemokine (C-X-C motif) ligand 2 17.7
Cxcl2 chemokine (C-X-C motif) ligand 2 109.2
Cxcl5 chemokine (C-X-C motif) ligand 5 145.6
Cxcl1 chemokine (C-X-C motif) ligand 1 100.0
Cxcl9 chemokine (C-X-C motif) ligand 9 13.3
Ccl2 chemokine (C-C motif) ligand 2 12.8
Ccl3 chemokine (C-C motif) ligand 3 28.7
Ccl8 chemokine (C-C motif) ligand 8 13.4
Il1b interleukin 1 beta 20.9
Il24 interleukin 24 23.7
Il6 interleukin 6 39.4
Mmp10 matrix metallopeptidase 10 15.8
Mmp12 matrix metallopeptidase 12 104.1
Mmp13 matrix metallopeptidase 13 62.5
Mmp3 matrix metallopeptidase 3 9.3
Mmp9 matrix metallopeptidase 9 6.0
Ppara peroxisome proliferator activated receptor alpha −8.6
Pparg peroxisome proliferator activated receptor gamma −4.3
Ptges prostaglandin E synthase 11.4
Ptgs2 prostaglandin-endoperoxide synthase 2 14.1
Krt16 keratin 16 116.0
Krt6a keratin 6A 86.2
t u m o rm o d e l ,i st h a ti tp r o d u c e ss q u a m o u sc e l lc a r c i n o m a s
from the nonglandular forestomach rather than adeno-
carcinomas from the glandular tissue that comprises the
majority of human gastric cancer [46]. Since this model was
dependent on the selective PPARδ agonist GW501516 [47],
it is important to note that the dose of GW501516 used
in the present and previous studies [19]i se q u i v a l e n tt o
daily oral doses of 3–10mg/kg that were previously shown to
speciﬁcally enhance PPARδ-dependent fatty acid oxidation
in mice [48]. In addition, PPARδ agonist GW7042, which
is almost identical to GW501516 in structure, potency,
and speciﬁcity, was inactive in inducing gene expression
in PPARδ knockout mice [49], suggesting that the tumor
promoting eﬀects of GW501516 and GW7042 are not due
to oﬀ-target eﬀects.
Tumors induced by GW501516 exhibited a distinct
inﬂammatory gene expression signature comprised predom-
inantly of chemokine, MMP, and S100 genes (Table S2). This
was unexpected in view of the lack of a similar signature
after treatment with GW501516 (Table S3), and the fact
that GW501516 induces an anti-inﬂammatory response in
macrophages [50] and protects the heart against oxidative
stress [51, 52]. Gene ontology analysis of gene expression in
the gastric tumors indicates that PPARδ, MMP12, MMP13,
Cxcl1, Cxcl5, S100A8, and S100A9 share both common and
disparate pathway interactions that likely contributed to the
tumorigenic phenotype (Figure 5). PPARδ is associated with
activation of genes related to proliferation (EGFR, Akt1) and
adhesion (Itgb2), whereas S100A9 is associated with angio-
genesis (Fgf2) and inﬂammation (Ager). Cxcl1 activates
proliferation (Mapk3, Mapk14, and Akt1), angiogenesis
(Fgf2), and invasion (MMP2, MMP9), and Cxcl5 activates
otherchemokines(Cxcl1,Cxcl2,andCxcl3)andPtgs2/Cox2.
This scheme reiterates the ability of S100A8 and S100A9
to act as ligands for Ager (advanced glycation end-product
receptor), which mediates acute and chronic inﬂammation,
tumor development, and metastasis [53, 54]. This paradigm
is also consistent with GW501516-induced activation of
Ptges and Ptgs2/Cox-2 expression [55, 56], which initiate
the production of prostacyclins [14] and arachidonic acid
metabolites[29]thatserveasPPARδ ligands[57].SinceCox-
2 inhibitors reduce inﬂammation-related gastrointestinal
carcinogenesis [58], and overexpression or deletion of Ptgs2
increases or suppresses tumorigenesis, respectively [59, 60];
this suggests cooperativity between PPARδ and inﬂamma-
tory signaling pathways in gastric tumorigenesis. The ability
of PPARδ to have an anti-inﬂammatory eﬀect in normal
cells [51, 52] and a proinﬂammatory eﬀect in tumors is
reminiscentofthedualrolesofTGF-βintumorcells[61,62].
TGFβ canfunctionasaproinﬂammatorycytokinetoactivate
S100A8 and S100A9 expression in the presence of activated
Ras [63] but acts as a repressor of inﬂammation-inducedPPAR Research 9
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Figure 5: Signaling networks associated with PPARδ and inﬂammatory and invasive gene expression. Common signaling pathways were
analyzed for six genes with the greatest changes in expression in gastric tumors (highlighted in blue) versus forestomach using Ariadne
Pathway Studio 7.1.
PPARδ expression in normal cells [64, 65]. The increased
expression of the PPARδ target gene, Agptl4, the TGFβ-
activated genes Runx1 and Runx2, and S100A8 and S100A9
in the gastric tumors indeed suggests a duality of function of
both PPARδ and TGFβ signaling in gastric tumorigenesis.
PPARδ isubiquitouslyexpressedingastrointestinaltissue
and gastric tumors [27], and GW501516 elicited increased
PPARδ nuclear staining and elevated pAkt in gastric epithe-
lium and tumors. PPARδ-dependant activation of Akt is
required for the growth-promoting and antiapoptotic eﬀects
of PPARδ [66–68], as shown by the delayed wound-
healing response of PPARδ-deﬁcient keratinocytes [57, 69].
Enhanced Krt6a and Krt16 expression in tumors further
suggests that PPARδ plays an important role in gastric
squamous cell diﬀerentiation and tissue renewal.
Tumors also exhibited reduced PPARγ and PPARα
expression that may have resulted, in part, from the negative
regulation of PPARγ by PPARδ [70]. PPARγ suppresses the
growth and invasion of human colon [71]a n dg a s t r i c[ 72,
73] and esophageal carcinoma cells [74], and both PPARγ
[75]a n dP P A R α have anti-inﬂammatory actions [76]. Thus,
reduction of PPARα and PPARγ expression may be an
additional mechanism for facilitating the proinﬂammatory
and tumor-promoting eﬀects of GW501516.
In summary, we describe a rapidly developing metastatic
gastric cancer model dependent on the tumor-promoting10 PPAR Research
eﬀects of GW501516 following carcinogen treatment, which
suggests a proinﬂammatory switch in PPARδ function. This
animal model will therefore be useful to delineate the role of
PPARδ in tumor initiation and progression and as a possible
target for early intervention.
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